Current Landscape
Peritoneal surface malignancies (PSM)—originating from gastric, colorectal, ovarian, appendiceal cancers, or primary mesothelioma—represent a significant therapeutic challenge. Standard systemic intravenous (IV) chemotherapy exhibits poor penetration into peritoneal nodules due to the blood-peritoneum barrier, limiting its efficacy and resulting in a purely palliative prognosis for most patients.
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel, minimally invasive drug delivery system designed to overcome these pharmacokinetic limitations. PIPAC aerosolizes liquid chemotherapy into a pressurized capnoperitoneum, enhancing drug distribution and tissue penetration within the abdominal cavity.
Currently, PIPAC is primarily utilized as a palliative treatment for patients with extensive, unresectable peritoneal metastases who have progressed on or are intolerant to systemic therapy. It is also being investigated as a neoadjuvant tool to downstage disease PCI (Peritoneal Cancer Index) to render patients eligible for cytoreductive surgery (CRS) and HIPEC.
Scientific Rationale and Mechanism of Action
The rationale for PIPAC is rooted in physical and physiological principles designed to optimize locoregional drug delivery.
A. Overcoming Interstitial Fluid Pressure
Solid tumors possess an elevated interstitial fluid pressure (IFP) that acts as a barrier to the outward diffusion of drugs from blood vessels into the tumor microenvironment. PIPAC addresses this by applying artificial hydrostatic pressure (typically 12 mmHg) within the abdominal cavity, counteracting the high intratumoral IFP and driving the chemotherapeutic agent into the tumor tissue via convection.
B. Optimization of Distribution (Aerosolization)
PIPAC utilizes a nebulizer system to convert a liquid chemotherapeutic solution into a fine, micron-sized aerosol mist. This mist behaves like a gas, enabling more homogenous distribution throughout the intricate surfaces and compartments of the entire peritoneal cavity compared to the liquid lavage used in HIPEC.
C. Favorable Pharmacokinetics
PIPAC achieves high local drug concentrations within the tumor tissue while maintaining low systemic absorption.
- Dose Reduction: The chemotherapeutic doses used in PIPAC are substantially lower (typically 10–20% of the standard systemic dose), significantly reducing systemic toxicity (e.g., neutropenia, renal failure).
- Tissue Penetration: Studies demonstrate drug penetration depth of up to several millimeters, exceeding that generally achieved with systemic or non-pressurized intraperitoneal therapy.
Patient Selection and Indications
Careful patient selection is paramount, particularly given the generally palliative nature of the current standard indications.
Inclusion Criteria (Standard Clinical/Trial Focus)
- Histological Confirmation: Confirmed peritoneal metastasis from:
- Gastric Cancer
- Ovarian/Fallopian Tube/Primary Peritoneal Cancer
- Colorectal Cancer
- Appendiceal Cancer
- Malignant Peritoneal Mesothelioma (MPM)
- Disease State: Unresectable peritoneal metastases (high PCI) or progression despite standard systemic chemotherapy
- Performance Status: ECOG 0–2 (patients must be able to tolerate laparoscopy and general anesthesia).
- Organ Function: Adequate hematologic, renal, and hepatic function to tolerate low-dose chemotherapy and potential systemic absorption.
- Malignant Ascites: Refractory malignant ascites where PIPAC can offer symptom relief.
Contraindications
- Inability to Perform Laparoscopy: Extensive adhesions, prior extensive surgery leading to frozen abdomen, or severe abdominal wall hernia preventing safe port entry.
- Uncontrolled Extra-abdominal Metastases: Significant burden of liver, lung, or bone disease that dictates prognosis more than the peritoneal disease.
- Terminal State/Poor Performance Status: ECOG >2.
- Severe Bowel Obstruction: Unless PIPAC is used solely to palliate ascites.
The PIPAC Procedure: Technical Overview
PIPAC is a standardized, repeatable surgical procedure performed under general anesthesia.
C. Postoperative Care
PIPAC is associated with rapid recovery. The procedure is typically repeated every 6 to 8 weeks for a cycle of three treatments, interspersed with systemic chemotherapy (“bidirectional therapy”).
A. Access and Staging
The procedure begins with a standard laparoscopy (typically 2-port technique).
- PCI Scoring: A comprehensive visual assessment of the peritoneal disease burden is performed to calculate the Peritoneal Cancer Index (PCI).
- Biopsy: Standardized biopsies are taken from selected quadrants for pathological assessment of tumor response (using scores such as the Peritoneal Overall Symptom Score, PROMS, or pathological response scores).
- Ascites Evacuation: All ascites is removed and measured.
B. Aerosol Application
- Device Setup: The sterile, single-use nebulizer (e.g., CapnoPen® or similar device) is inserted through a balloon trocar and connected to a high-pressure injector pump (similar to those used in cardiology).
- Chemotherapy Delivery: The injector nebulizes the chemotherapeutic solution (e.g., Cisplatin and Doxorubicin for ovarian/gastric/mesothelioma; Oxaliplatin for colorectal) as a fine mist into the pre-established 12 mmHg COâ‚‚ capnoperitoneum.
- Incubation: The aerosol is maintained within the closed abdominal cavity under pressure for a predetermined "incubation period" (typically 30 minutes) to allow for drug uptake.
- Evacuation: Following incubation, the remaining aerosolized waste is evacuated through a closed suction system equipped with specific filters (e.g., activated carbon) to prevent environmental contamination.
Safety and Occupational Hazards
Because PIPAC utilizes aerosolized cytotoxic agents, strict occupational safety protocols are mandatory.
Surgical Team Protection
- Closed System: The procedure is designed as a closed air circuit. Trocar tightness must be monitored by observing the COâ‚‚ leak rate.
- Laminar Air Flow: The operating room must possess laminar air flow to facilitate rapid air exchange.
- Personal Protective Equipment (PPE): High-level PPE, including specialized respiratory masks (e.g., FFP3 or equivalent), double gloving, and eye protection, is required during the nebulization and evacuation phases.
- Remote Operation: The injection pump should be operated remotely from outside the operating room or behind a protective shield.
- Monitoring: Occupational biomonitoring (blood/urine tests for Platinum/Doxorubicin) may be part of institutional protocols for regular team members.
Clinical Evidence and Outcomes
The majority of published data on PIPAC consists of phase I/II trials, retrospective case series, and registry data, primarily originating from European centers.
Key Findings:
- Feasibility and Safety: PIPAC is highly feasible (>90% success in repeating cycles) and has a favorable safety profile. Major complications (Clavien-Dindo III/IV) are low (typically <5–10% per cycle).
- Response Rates: Objective histological tumor response (e.g., according to the Peritoneal Regression Grading Score) has been observed in 50–70% of heavily pretreated patients across various histologies.
- Survival: Published median overall survival results vary but show promising trends:
- Gastric (progression on IV chemo): 10–15 months.
- Ovarian (platinum-resistant): 11–17 months.
- Colorectal: 15–16 months.
- Quality of Life (QoL): Validated QoL instruments (e.g., EORTC QLQ-C30) often show stabilization or improvement in patient-reported outcomes, particularly regarding ascites symptoms and pain control.
Limitations:
- Palliative Focus: Data showing cure is nonexistent; PIPAC is currently a disease-stabilizing or downstaging therapy.
- Lack of strong Phase III Data: Definitive high-level evidence comparing PIPAC to modern systemic therapy alone is still pending from large, randomized phase III trials.
Future Directions and Innovations
The field of PIPAC is rapidly evolving with several active areas of research.
- Electrostatic Precipitation (ePIPAC): A technique using a high-voltage electrode to ionize the aerosol droplets, utilizing electrostatic forces to drive the drug particles deeper and more evenly into the tissue. Preliminary studies suggest enhanced uptake.
- Bidirectional/Combination Therapy: Refining protocols for combining PIPAC with systemic chemotherapy, targeted therapies (e.g., bevacizumab), or immunotherapy.
- Neoadjuvant Setting: Investigating the use of PIPAC earlier in the disease course to downstage unresectable PSM (e.g., gastric cancer with PCI >10) to make patients eligible for curative-intent CRS/HIPEC.
- Prophylactic PIPAC: Exploring the use of PIPAC in high-risk patients (e.g., T4 gastric cancer) to prevent the development of peritoneal metastases.
Conclusion
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) represents a promising technological advance in the management of peritoneal surface malignancies.
By leveraging the physical principles of aerosolization and pressure, it offers a novel method to enhance local drug delivery while minimizing systemic side effects.
While currently a vital tool primarily within specialized clinical trial settings for palliative patients, PIPAC holds potential to remodel the treatment algorithm for PSM if randomized phase III data validate its survival and quality-of-life benefits.
Disclaimer
This guide is intended for medical professionals and is based on evidence available up to early 2024.
Local regulatory guidelines regarding experimental therapies must be observed.